Cambrex’s Post

PhycoLife is welcoming investments from public on Swarmer and the response has been incredible! In just 24 hours of their launch they’ve raised over $560,000 with the support of 239 investors! 🎉 📈 Investment Highlights: * Maximum Raise Goal: $3,000,000 AUD * Price per Share: $6 AUD * Minimum Investment: $270 AUD 🔥 Hurry! Limited shares are available. This is your chance to be part of PhycoLife's growth as they expand their processing and refinery plant, enhance their product quality to meet nutraceutical and medical standards, and secure medical regulatory approvals. Invest now and be a shareholder in PhycoLife—opportunity closes once they hit their maximum raise goal! 🔗 Invest via: https://lnkd.in/gJD8tW-6 ✅ Always consider the general CSF risk warning & offer document before investing. #phycolife #InvestmentOpportunity #swarmer #OwnYourShare

https://lnkd.in/dJeZ2KVk Breaking Ground in Pharma Supply Chain: Check out our latest article on The Wolf Practice website, diving deep into the game-changing strategies for tackling serialization challenges! 🚀 💼 #PharmaInnovation #SupplyChainSolutions #TheWolfPractice

Following our recent acquisition of Reach Separations, here’s what Peter Ridgway, Business Development Director at Reach Separations, had to say: "Becoming part of the CatSci Ltd Group will enhance and strengthen Reach Separations’ ability to deliver excellence in chromatography. Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset. As one of the founders of Reach Separations, I am delighted to join forces with CatSci to deliver strong growth and expand separation science into new marketplaces." This strategic acquisition marks a significant milestone for CatSci and enhances our ability to deliver programmes where rapid purification by chromatography is often essential to expediting clinical development. Together with Reach, we will drive forward our shared mission to deliver excellence in medicines development.   Learn more about how this acquisition will solve our customers' separation science challenges: https://lnkd.in/ebprErGt #ExcellenceInMedicinesDevelopment #ProudToBeCatSci #DrugDevelopment #MedicinesDevelopment

Thoughts on this? >> Icahn gives up seat on Illumina board, backing away from challenge to diagnostics company >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #productmarketing #biotech

Thoughts on this? >> Icahn gives up seat on Illumina board, backing away from challenge to diagnostics company >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharmaceutical #pharma #biotech

Come check us out and see for yourself how we can help you and your practice soar!

"We are thrilled to collaborate with GPC to enhance the global impact of our services. Dr Chandrashekaran Siddamadappa, Chairman and Managing Director of Vipragen Biosciences said that "This partnership strengthens our commitment to delivering high-quality solutions while ensuring stringent compliance with evolving regulatory standards". This collaboration could bring lot more coverage across the regulatory and testing services. The aim is to ensure a foolproof approach to the clients for their product development to registration at various regulatory junctures. With the excellent track record for conducting various research and regulatory programs, both Vipragen and GPC are poised to go from multi-counter approach to one-stop solution provider. #drugdiscovery #pharmaceutical #chemicals #nutraceutical #regulatorycompliance #CRO #safetydata #toxicology

#DCAT is around the corner, and we are looking forward to the upcoming discussions with our customers. Unfamiliar with #Cambrex? Let's arrange an introductory meeting and learn more about each other's organizations. #CDMO #smallmolecules #API #pharmaceuticalmanufacturing

Thoughts on this? >> Siduma, a biotech from Arvinas' scientific founder, shutters due to 'financing environment' >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #healthcare #pharma #pharmaceutical